Surgery Partners, Inc. (NASDAQ: SGRY) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.69 | Insider Own | - | Shs Outstand | 130.79M | Perf Week | -5.45% |
| Market Cap | 1.75B | Forward P/E | 24.76 | EPS next Y | 0.54 | Insider Trans | 0.01% | Shs Float | 77.94M | Perf Month | -6.25% |
| Enterprise Value | 5.55B | PEG | - | EPS next Q | 0.08 | Inst Own | 125.12% | Short Float | 16.62% | Perf Quarter | -6.18% |
| Income | -89.00M | P/S | 0.52 | EPS this Y | 166.36% | Inst Trans | - | Short Ratio | 7.26 | Perf Half Y | 8.01% |
| Sales | 3.37B | P/B | 0.56 | EPS next Y | 17.73% | ROA | -1.10% | Short Interest | 12.95M | Perf YTD | -13.59% |
| Book/sh | 23.72 | P/C | 8.05 | EPS next 5Y | 6.94% | ROE | -5.21% | 52W High | 23.44 -43.05% | Perf Year | -38.08% |
| Cash/sh | 1.66 | P/FCF | 10.03 | EPS past 3/5Y | - | ROIC | 4.39% | 52W Low | 11.41 17.00% | Perf 3Y | -59.42% |
| Dividend Est. | - | EV/EBITDA | 5.86 | Sales past 3/5Y | 9.23% 12.21% | Gross Margin | 21.37% | Volatility | 4.87% 4.72% | Perf 5Y | -73.18% |
| Dividend TTM | - | EV/Sales | 1.65 | EPS Y/Y TTM | 48.12% | Oper. Margin | 11.89% | ATR (14) | 0.70 | Perf 10Y | -33.35% |
| Dividend Ex-Date | - | Quick Ratio | 1.78 | Sales Y/Y TTM | 8.12% | Profit Margin | -2.63% | RSI (14) | 39.61 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.95 | EPS Q/Q | -41.18% | SMA20 | -4.84% | Beta | 1.89 | Target Price | 18.00 |
| Payout | 0.00% | Debt/Eq | 1.13 | Sales Q/Q | 2.78% | SMA50 | -10.57% | Rel Volume | 1.92 | Prev Close | 13.93 |
| Employees | 16,000 | LT Debt/Eq | 1.10 | Earnings | Nov 09 | SMA200 | -8.96% | Avg Volume | 1.98M | Price | 13.35 |
| IPO Date | Sep 30, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 72.58% 2.27% | Net Debt/EBITDA | 4.01 | Volume | 3,806,232 | Change | -4.16% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-11-26 | Reiterated | Raymond James | Market Perform | $18 |
| Aug-11-26 | Reiterated | RBC Capital | Outperform | $20 → $19 |
| May-06-26 | Reiterated | Jefferies | Buy | $15 → $17 |
| Apr-20-26 | Reiterated | Jefferies | Buy | $16 → $15 |
| Mar-11-26 | Reiterated | US Capital Advisors | $21 | |
| Mar-04-26 | Reiterated | Jefferies | Buy | $30 → $16 |
| Mar-04-26 | Reiterated | RBC Capital | Outperform | $20 |
| Mar-03-26 | Reiterated | Jefferies | Buy | $40 → $30 |
| Dec-18-25 | Reiterated | Mizuho | Outperform | $22 → $19 |
| Nov-21-25 | Reiterated | Barclays | Equal Weight | $31 → $18 |
Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical venues include both ambulatory surgery centers and dedicated surgical hospitals, delivering non-urgent surgical procedures across various specialties such as gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The surgical hospitals additionally offer comprehensive ancillary services, including diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care. The dedicated Ancillary Services segment further encompasses multi-specialty physician practices, urgent care facilities, and anesthesia services. By December 31, 2021, the company's portfolio consisted of 126 surgical facilities—specifically, 108 ambulatory surgical centers and 18 surgical hospitals—situated across 31 states. Founded in 2004, Surgery Partners, Inc. maintains its headquarters in Brentwood, Tennessee.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,367 | 3,309 | 3,114 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,647 | 2,544 | 2,369 | — | — | — | — | — | — | |
| Gross Profit | 719 | 765 | 746 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 628 | 523 | 139 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | -309 | -147 | 258 | — | — | — | — | — | — | |
| Operating Income | 400 | 390 | 349 | — | — | — | — | — | — | |
| Interest Expense | 669 | 273 | 202 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 370 | 0 | 0 | — | — | — | — | — | — | |
| Net Income Before Taxes | 103 | 117 | 147 | — | — | — | — | — | — | |
| Income Taxes | 22 | 18 | 135 | — | — | — | — | — | — | |
| Consolidated Net Income | -89 | -78 | -168 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 82 | 99 | 13 | — | — | — | — | — | — | |
| Net Income | -89 | -78 | -168 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.69 | -0.61 | -1.33 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.69 | -0.61 | -1.33 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.69 | -0.61 | -1.33 | — | — | — | — | — | — | |
| EBITDA | 947 | 566 | 501 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.51 | 0.59 | 0.86 | — | — | — | — | — | — | |
| Gross Margin | 21.35 | 23.12 | 23.96 | — | — | — | — | — | — | |
| Operating Margin | 11.88 | 11.79 | 11.21 | — | — | — | — | — | — | |
| Net Margin | -2.64 | -2.36 | -5.39 | — | — | — | — | — | — | |
| Shares Outstanding | 129 | 127 | 126 | — | — | — | — | — | — | |
| Market Capitalization | 1,722 | 1,962 | 2,667 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| DeLuca Teresa | Director | Aug 18 '26 | Buy | 14.34 | 21,250 | 304,713 | 68,093 | Aug 20 |
| Evans Jason Eric | Chief Executive Officer | Mar 16 '26 | Sale | 12.47 | 20,400 | 254,388 | 920,386 | Mar 16 |
| Doherty David T | Chief Financial Officer | Mar 16 '26 | Sale | 12.50 | 8,867 | 110,838 | 221,679 | Mar 16 |
| Brittenham Marissa | Chief Strategy Officer | Mar 13 '26 | Sale | 12.54 | 3,657 | 45,859 | 94,196 | Mar 16 |
| Burkhalter Danielle | Chief Human Resources Officer | Mar 13 '26 | Sale | 12.83 | 3,469 | 44,507 | 76,864 | Mar 16 |
| Baldock Jennifer | Chief Admin & Dev Officer | Mar 12 '26 | Sale | 13.17 | 5,798 | 76,360 | 326,474 | Mar 16 |
| Burkhalter Danielle | Chief Human Resources Officer | Mar 06 '26 | Sale | 13.60 | 7,736 | 105,210 | 37,103 | Mar 09 |
| Brittenham Marissa | Chief Strategy Officer | Mar 06 '26 | Sale | 13.70 | 8,785 | 120,355 | 54,623 | Mar 09 |
| Evans Jason Eric | Chief Executive Officer | Mar 06 '26 | Sale | 13.79 | 11,462 | 158,061 | 662,680 | Mar 09 |
| Baldock Jennifer | Chief Admin & Dev Officer | Mar 06 '26 | Sale | 13.70 | 10,082 | 138,123 | 332,272 | Mar 09 |
| Webb William Trenton | American Group President | Mar 06 '26 | Sale | 13.93 | 272 | 3,789 | 74,249 | Mar 09 |
| Doherty David T | Chief Financial Officer | Mar 06 '26 | Sale | 13.84 | 14,574 | 201,704 | 88,803 | Mar 09 |
| Webb William Trenton | American Group President | Mar 05 '26 | Sale | 13.86 | 1,794 | 24,865 | 72,455 | Mar 09 |
| Bane Harrison R. | National Group President | Sep 04 '25 | Sale | 22.48 | 9,339 | 209,940 | 117,181 | Sep 08 |
| Maryland Patricia Anne | Director | Aug 11 '25 | Sale | 22.74 | 20,018 | 455,209 | 4,565 | Aug 15 |